Genomewide Screen for Synthetic Lethal Interactions with Mutant KRAS in Lung Cancer
Abstract
Many factors are known to contribute to the development of lung cancer; one of the important contributing ones is genetic mutations. For example, KRAS mutations account for 22% of lung cancer cases. Thus, researchers have been trying hard to develop drugs against mutant KRAS. However, to date no effective pharmacological inhibitors targeting mutant RAS have reached the clinic for various reasons. Therefore, the search is still going on. Synthetic lethal approach is a new concept that RAS mutant cancer cells rely on other genes or pathways to survive. Thus, these genes or pathways serve as potential targets for lung cancer therapy. Our proposed work uses the same concept but with a novel approach. Accordingly, this application addresses the Lung Cancer Research Program Areas of Emphasis "Identify innovative strategies for prevention and treatment of early and/or localized lung cancer." The success of this study will help develop a better strategy for lung cancer treatment and directly benefit lung cancer patients of military Service members, Veterans, and their families.
Document Details
- Document Type
- DoD Grant Award
- Publication Date
- Jan 31, 2017
- Source ID
- W81XWH1610287
Entities
People
- Yin-Yuan Mo
Organizations
- United States Army
- University of Mississippi